Completed PHASE2 INTERVENTIONAL 1-arm NCT00237198

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Sponsor: Chugai Pharmaceutical

Conditions Postmenopausal Women With Advanced Breast Cancer

Interventions Letrozole

Updated 6 times since 2017 Last updated: Feb 21, 2017 Started: Mar 31, 2004 Primary completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Postmenopausal Women With Advanced Breast Cancer and is currently completed. Chugai Pharmaceutical leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chugai Pharmaceutical
Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bunkyo-ku, Japan , Chuo-ku, Japan , Cyuo-ku, Japan , Fukuoka, Japan , Fukushima, Japan , Kashiwa, Japan , Kitaadachi-gun, Japan , Koto, Japan , Kurashiki, Japan , Kure, Japan and 11 more locations